Diversified Tech Biogen Idec Sees Plegridy Regulatory Delay in the United StatesBy Stefan LevyApril 1, 2014 Before the markets opened Monday, Biogen Idec announced the FDA has extended its regulatory review for Plegridy by three months.…
Business & Finance Auspex Pharmaceuticals Posts In-Line Year-End Results, Data From FIRST-HD Expected in the Fourth QuarterBy Sean CampbellApril 1, 2014 Auspex Pharmaceuticals reported year-end operating results on Thursday afternoon, March 27, in the company’s first update since its initial public…
BioTech Achillion Pharmaceuticals, Inc. Fourth Quarter 2013 Earnings Uneventful; Nuke Data in Third Quarter 2014 Is Key Catalyst of the YearBy Ryan WallaceMarch 19, 2014 Achillion Pharmaceuticals, Inc. reported net loss for the quarter of $13.4 million with a per-share loss of $0.14 versus our…